Medication Review: What are guselkumab's other FDA indications and how might that affect patient care?
GHAPPcast20 Helmi 2025

Medication Review: What are guselkumab's other FDA indications and how might that affect patient care?

Thank you to Johnson & Johnson for your support of this Medication Review Video Module.

In this video, Anne Feldman, NP, from Cleveland Clinic, discusses Guselkumab (Tremfya), an FDA-approved treatment for adults with moderate to severe ulcerative colitis, plaque psoriasis, and psoriatic arthritis. With promising Phase 3 clinical trial results, Guselkumab is expected to receive FDA approval for Crohn’s disease, making it a potential first-line advanced therapy or an option for patients who have failed other advanced treatments.

Beyond gut-related inflammation, extraintestinal manifestations (EIMs)—affecting the skin, joints, and eyes—are common in IBD (Inflammatory Bowel Disease), especially Crohn’s disease. Up to 40% of IBD patients experience EIMs, sometimes even before their IBD diagnosis. Because Guselkumab is already FDA-approved for psoriasis and psoriatic arthritis, it offers a multisystem treatment approach, addressing both IBD and associated autoimmune conditions. By targeting multiple inflammatory pathways, this therapy has the potential to reduce disease burden and significantly improve quality of life.

For more information on IBD treatment strategies and Guselkumab’s role in patient care, visit the Gastroenterology & Hepatology Advanced Practice Provider (GHAPP) website or download the GHAPP ACE mobile app.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(164)

Linerixibat Medication Review

Linerixibat Medication Review

Christina Hanson, FNP, and Dr. Marcelo Kugelmas of South Denver Gastroenterology review linerixibat, an ileal bile acid transporter (IBAT) inhibitor, and its role in managing cholestatic pruritus in p...

22 Syys 13min

Podcast: Managing Fatigue and Pruritus in Your Patients With PBC

Podcast: Managing Fatigue and Pruritus in Your Patients With PBC

How can clinicians better recognize and manage itching and fatigue in primary biliary cholangitis (PBC)? In this podcast, hepatology clinicians from RUSH University Medical Center discuss the impact o...

15 Syys 15min

Podcast: How to Screen and Diagnose Cholestatic Liver Diseases

Podcast: How to Screen and Diagnose Cholestatic Liver Diseases

In this episode, HoChong Gilles of the Richmond VA Medical Center, and Alison Moe of Atlanta Gastroenterology discuss a practical, step-by-step approach to screening for and diagnosing cholestatic liv...

25 Elo 20min

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing ...

18 Elo 48min

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module.In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hep...

11 Elo 4min

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephal...

4 Elo 2min

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussio...

23 Heinä 7min

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the...

30 Kesä 17min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
aamukahvilla
psykopodiaa-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
meditaatiot-suomeksi
rss-kuumilla-aalloilla
tiedenaiset-podcast
rss-pitaisko-erota
rss-pt-paahtio
voi-hyvin-meditaatiot-2
rss-uplevel-by-sonja-hannus
rss-duodecim-lehti
rss-hereilla
selviytyjat-tarinoita-elamasta
rss-palaudu-synnytyksesta-podcast
rss-terapiaklubi
junnut-pelissa
rss-kehtaanko-kysya-podcast-aideille
rss-mighty-finland-podcast
terapiassa